Verrica Will Present New Clinical Trial Data in October
The company will unveil research on molluscum contagiosum and skin cancer treatments at upcoming medical conferences.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Is early medical intervention generally preferable to a watch-and-wait approach for common skin conditions?
Verrica Pharmaceuticals will share new clinical data at the Fall Clinical Dermatology Conference and the 2026 PeDRA Annual Conference between October 8 and October 17, 2026. Findings include pooled analyses on the efficacy of YCANTH for treating molluscum contagiosum.
Why it matters
This data provides clinicians with a scientific rationale for early intervention when treating molluscum contagiosum. Additionally, the presentation offers updates on potential abscopal effects of the developmental drug VP-315 for skin cancer patients.
A post-hoc pooled analysis of two Phase 3 trials showed YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle. By Day 84, the Kaplan-Meier cumulative complete clearance was 60.1% for VP-102 versus 19.9% for vehicle.
The players
Verrica Pharmaceuticals
This is a medical dermatology company that develops innovative treatments for skin diseases and conditions.
The details
The analysis of VP-315 examined untreated, non-target lesions in subjects from a Phase 2 study to explore potential abscopal effects in basal cell carcinoma tumors. Verrica intends to focus on basal cell and squamous cell carcinomas as the primary indications for the future development of VP-315.
Timeline
Verrica presents data at the Fall Clinical Dermatology Conference from October 8-11, 2026.
A poster reception occurs on October 15, 2026, at the 2026 PeDRA Annual Conference.
Data presentations at the 2026 PeDRA Annual Conference run from October 15-17, 2026.
The Big Picture
The upcoming presentations extend the existing research program for VP-315 in basal cell and squamous cell carcinomas. This clinical focus represents a strategic effort by the company to expand its therapeutic reach beyond existing FDA-approved treatments.
These findings provide physicians with additional data to support the use of YCANTH as a treatment for molluscum contagiosum. The ongoing research into VP-315 could eventually expand available non-surgical treatment options for patients with basal and squamous cell carcinomas.
The takeaway
Clinicians should monitor these upcoming conferences for updated clinical evidence regarding the speed and efficacy of molluscum contagiosum treatments. Patients currently managing skin conditions should consult their dermatologists to discuss how these new study results may influence their long-term care plans.
Further reading
Learn more about the latest developments in Cancer research and treatments.
More information
For detailed specifications on the treatment, visit the YCANTH product information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Is early medical intervention generally preferable to a watch-and-wait approach for common skin conditions?
